CIAM
AXSM icon

Caitong International Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Caitong International Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-415
Closed -$75.8K – 2612
2025
Q4 		$75.8K Buy
+415
New +$57.9K 0.02% 551
2025
Q3 		– Sell
-289
Closed -$30.2K – 1952
2025
Q2 		$30.2K Buy
289
+75
+35% +$7.94K 0.02% 400
2025
Q1 		$25K Buy
+214
New +$24.4K 0.02% 704

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caitong International Asset Management's AXSM Position: Q1 2026 in Review

Caitong International Asset Management sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 415 shares — an estimated $75.8K sold.

Caitong International Asset Management first reported a position in AXSM in Q1 2025 and held it in 3 quarters. The position peaked at $75.8K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Caitong International Asset Management reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caitong International Asset Management sold 415 Axsome Therapeutics shares in Q1 2026, an estimated $75.8K.
  • Caitong International Asset Management first reported a position in Axsome Therapeutics in Q1 2025 and held it in 3 quarters.
  • Caitong International Asset Management's Axsome Therapeutics position peaked at $75.8K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.